Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 17, 2023 (4 years ago)

Glimepiride Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: recalling drug products following an FDA inspection.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Glimepiride Tablets, USP, 4 mg, RX, Packaged as a) 100-count bottle, NDC# 68001-179-00; b) 500-count bottle, NDC# 68001-179-03, Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213. INDIA. For BluePoint Laboratories

Affected NDCs 68001-0179-00 68001-0179-03

Compare with the code on your package — it is the most precise check available.

Drug: Glimepiride Category: Diabetes Medication

Recalling firm
Amerisource Health Services LLC
NDC code
68001-179-00
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0759-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Glimepiride recalls

See all
Class III · Low risk

Glimepiride Tablets

Misprint on tablet

Ongoing Other Dr. Reddy's Laboratories, Inc. D-0313-2024
Class III · Low risk

Glimepiride Tablets

Misprint on tablet

Ongoing Other Dr. Reddy's Laboratories, Inc. D-0312-2024
Class II · Moderate risk

Glimepiride USP

CGMP deviations.

Terminated cGMP deviation PD-Rx Pharmaceuticals, Inc. NDC 43063-0587-90 D-0559-2023
Class II · Moderate risk

Glimepiride Tablets USP

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-8066-9 D-0527-2023
Class II · Moderate risk

Glimepiride Tablets

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-8095-9 D-0517-2023

Other recalls by Amerisource Health Services LLC

All 2023 recalls
Class III · Low risk

Primidone Tablets

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Amerisource Health Services LLC D-0537-2026
Class III · Low risk

Primidone Tablets

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Amerisource Health Services LLC D-0536-2026
Class II · Moderate risk

Oxycodone Hydrochloride Tablets

Defective container: card seal defects (weak/non-existent seals), leading to the tablets falling out of their cavities.

Ongoing Packaging defect Amerisource Health Services LLC NDC 68084-354-01 D-0338-2026